A new scientific review on the potential benefits of marijuana in treating brain disorders says that in addition to THC and CBD produced by the cannabis plant, “a diverse array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids” may also “demonstrate diverse pharmacological activities” and could offer therapeutic applications.
Such compounds include THCV, CBDV and CBG.
“Their antioxidant, anti-inflammatory and neuromodulatory effects position them as promising agents in treating neurodegenerative disorders,” says the report, authored by a pair of researchers from the Center for Dementia Research at the Nathan Kline Institute for Psychiatric Research in New York and released last month through Preprints.org.
Authors evaluated available scientific literature about minor cannabinoids and conditions such as epilepsy, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and substance and alcohol use disorders. They found evidence not only of neuroprotective effects but also other beneficial outcomes.
“The therapeutic potential of Cannabis sativa extends well beyond the widely studied CBD,” the report says, “encompassing a diverse range of lesser‐known phytocannabinoids that show promise in addressing various neurological disorders.”
“While research has extensively examined the neuropsychiatric and neuroprotective effects of Δ9-THC,” it adds, “other minor phytocannabinoids remain underexplored.”
Hellbound and Down 